Eli Lilly and Co. punched up its spending on federal lobbying in the third quarter as it focused on market access and pricing reform in Europe, trade issues and the health care overhaul, among other matters.
The Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.
Lilly lobbied on trade issues involving China, Russia and Vietnam. It also lobbied on pricing reform in Germany and Greece and market access in Poland and Italy, according to a report filed with the clerk of the House of Representatives. It lobbied on hospital discounts, patient safety issues, counterfeit medicines, financial derivatives and the health care overhaul, which promises more customers for drugmakers by covering millions of uninsured people.
Congress passed the overhaul in March, and it will be rolled out over the next several years.
Besides Congress, Lilly also lobbied the Food and Drug Administration, the U.S. Trade Representative, the Patent and Trademark Office and the departments of Agriculture, Commerce, State, Health and Human Services and Homeland Security, according to the disclosure report filed Oct. 18 with the House clerk's office.